Mechanism-Guided Development of Targeted Cancer Therapies

• 342 · PDF LYW-105: A novel bispecific antibody-drug conjugate with enhanced antitumor efficacy and broader therapeutic index Qianqian Zhao, Zhangsheng Lu, Xun Cao, Xiaobing Tang, Liguo Wang, Peixiang Liu, Lu Wang, Jiajie Feng, Cexiong (Winston) Fu
• 343 · PDF Role of BEN domain protein 4 (BEND4) in prostate cancer (PCa) and the effect of silencing BEND4 in PCa cell lines Janani Harikrishnan, Gnanasekar Munirathinam
• 344 · PDF TIP60 mediates chemoresistance by reducing cisplatin-DNA adduct formation and enhancing their repair Madhavi P. Kadakia, Akshay Hira, Caroline McLaughlin, Michael Craig, Ramzi Nahhas, Jin Zhang, Mike Kemp
• 345 · PDF Therapeutic restoration of p53 via engineered synthetic mRNA analogs in p53 mutant cancer Yong Ho Heo, Seung-Hyun Shin, Youngjin Han, Sol-Bi Shin, Innah Kim, Soye Jeon, Aran Park, Jooyun Byun, Daejin Kim, In Young Choi
• 346 · PDF TIP60 regulates PTEN expression, acetylation, and localization in cisplatin-resistant SCC Caroline McLaughlin, Akshay Hira, Madhavi Kadakia
• 347 · PDF Dual dependency of large cell neuroendocrine carcinoma on Ras and ASCL1 oncogenic pathways Alyssa Cordes, Michael J. Peyton, Urooba Nadeem, Shreoshi Pal Choudhuri, Seth Hamilton, Shruti Raghavan, Kimberley Avila, Luc Girard, John D. Minna, Benjamin J. Drapkin
• 348 · PDF GFH603: A molecular glue-like allosteric activator of the KEAP1-CUL3 E3 ligase complex for targeting NRF2-activated tumors Xiang Yu, Tao Jiang, Tao Liang, Feng Yan, Li Wang, Jingyang Zhang, Siyuan Le, Fusheng Zhou, Jiong Lan, Qiang Lu
• 349 · PDF Next-generation sequencing and phospho-kinase analysis expose partner-specific profiles in CD74-ROS1 fusions Jasmine Vargas, Julia Olivieri, Georgios Pantouris
• 350 350 VHL loss-driven accumulation of GCN5L1 drives clear cell Renal Cell Carcinoma by regulating acetylation of mitochondrial proteins and metabolic reprogramming Bradley R. Webster, Kumarkrishna Raychaudhuri, Christopher Ricketts, W. Marston Linehan, Ramaprasad Srinivasan
• 352 · PDF Long non coding RNA plasmacytoma variant translocation 1 alternative splicing in prostate carcinogenesis Seidu Adams, Dominique Weatherall, Rachel E. Bonacci, Chinedum Chukwuemeka Udekwu, Olorunseun O. Ogunwobi
• 353 353 Pancreatic cancer modeling in germline BRCA2 mutation carriers Yi Xu, Nur Yucer, Alyssa Okimoto, Bobbie J. Rimel, Kate Lawrenson, Pei Wang, Simon A. Gayther
• 354 · PDF Distinct response profiles of TROP2-targeting ADCs Dato-DXd and sac-TMT across a large panel of cancer cell lines Janneke J. T. M. Melis, Eef F. P. Smits, Karsten P. F. van Doorn, Tsang W. Lam, Jeroen A. D. M. de Roos, Daphne J. F. Kluitmans, Jeffrey J. Kooijman, Guido J. R. Zaman, Jorg C. J. Benningshof
• 355 · PDF Co-expression of FIH1 and IL-12 in oncolytic HSV-1 blocks Notch signaling and enhances anti-tumor immunity Karina Vazquez-Arreguin, Balveen Kaur
• 356 · PDF Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers Argun Akcakanat, Ecaterina E. Dumbrava, Kurt W. Evans, Ran Zhang, Ming Zhao, Amber Kennon, Xiaofeng Zheng, Stephen M. Scott, Erkan Yuca, Gabriela Raso, Elisabeth K. Kong, Yasmeen Rizvi, David Hong, Masha V. Poyurovsky, Guillermina Lozano, Anil Korkut, Funda Meric-Bernstam
• 357 · PDF DIRAS3 mimetic peptide achieves dual MAPK and PI3K pathway suppression across KRAS hotspot mutations Gamze Bildik, Junchen Liu, Weiqun Mao, Hailing Yang, John F. Hancock, Steven W. Millward, Robert C. Bast, Zhen Lu
• 358 · PDF EV-based delivery of chemically modified siRNA achieves MRTX1133-comparable efficacy in KRAS G12D-mutant pancreatic cancer Hyo Kyeong kim, Yujeong Choi, Kyoung Hwa Kim, Jae Hwan Kim, Shung Hyun An, Dae Ho Bae, Minyoung Lee, Jihwa Chung, Seok-Hyun Kim, Kihwan Kwon
• 359 359 Development of a collection of cell lines from a genetically engineered mouse model of DICER1 syndrome-associated sarcoma for therapeutic assessment Lanlan Fang, Joyce Yu-Han Zhang, Shary Chen, Yannes Wai Yan Choi, Yemin Wang, David Huntsman
• 360 · PDF TM4SF1 as a promising ADC target for KRAS-mutated cancers Sewon Park, Youwon Lee, Jae-Sang Hwang, Ju-hyeon Lee, Mi Ran Yun, Byoung Chul Cho
• 362 · PDF Targeting RUNX transcriptional activity reduces tumor heterogeneity and aggressiveness in triple-negative breast cancer Natalia Brenda Fernandez, Facundo Luis Couto, María Sofía Sosa, Natalia Rubinstein
• 363 · PDF Targeting scaffold/matrix associated regions in pancreatic ductal adenocarcinoma: A novel carbazole-derived therapeutic Jack Prochnau, Daisy Medina, Jian Huang, Phat Do, Deepika Singh, Panneerdoss Subbarayallu, Stanton McHardy, Manjeet K. Rao
• 364 364 EMT-driven alterations promote dependency on nuclear kinase VRK1 activity to synergize with immune therapy in triple negative breast cancer Priyanka Sahu, Raymond Liu, Sergey Shmelkov, Uger Ozerdem, William C. Hahn, Jonathan So

在会议检索中浏览本分会场